No Data
No Data
Kyverna, Cabaletta Started at Buys by UBS on CAR T Therapy Potential
UBS Initiates Cabaletta Bio(CABA.US) With Buy Rating, Announces Target Price $10
Cabaletta Bio Initiated With a Buy at UBS
Cabaletta Bio Outlines Future Trials and Development Strategy
Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $26
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
No Data
No Data